News and Updates
FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies
The US Food and Drug Administration (FDA) has approved a 20% immune globulin solution for subcutaneous injection (Xembify, Grifols) to treat primary immunodeficiencies in patients as young as 2 years old, according to a company statement.The approval includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies… (Medscape)
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies